AnaptysBio Announces December Investor Conferences
In a recent update, AnaptysBio, Inc. (NASDAQ: ANAB) shared its plans to actively participate in significant investor conferences this December. Based in San Diego, AnaptysBio is recognized as a clinical-stage biotechnology company that specializes in innovative immunology therapeutics, aimed at addressing various autoimmune and inflammatory conditions.
Upcoming Conference Details
Company leadership, including CEO Daniel Faga, is set to engage with investors through presentations and discussions during these eventful days. Here are the specifics:
Piper Sandler 37th Annual Healthcare Conference
This conference will feature a format that includes a fireside chat alongside dedicated one-on-one investor meetings. Attendees can expect insights from the company’s vision and developments.
Date and Time: Tuesday, December 2, 2025, at 1:30 PM ET
Evercore 8th Annual Healthcare Conference
The second prominent conference will also include a fireside chat followed by one-on-one meetings, providing an excellent platform for detailed discussions.
Date and Time: Wednesday, December 3, 2025, at 7:55 AM ET
Live Webcast Availability
For those unable to attend, live webcasts of the sessions will be accessible in the investor section of the AnaptysBio website. There will also be an option to replay the webcasts for up to 30 days following the events, making it easy for investors to catch up on this critical information.
About AnaptysBio
AnaptysBio, Inc. is on a mission to advance transformative immunology-based therapies. The company’s diverse pipeline features promising candidates such as rosnilimab, designed to target pathogenic T cells, and is currently completing a Phase 2b trial aimed at tackling rheumatoid arthritis. Moreover, their therapy ANB033, a CD122 antagonist, is under investigation in a Phase 1b clinical trial for celiac disease, with ambitions to broaden its application into other indications.
In addition to pipeline advancements, AnaptysBio has made significant strides in co-developing therapeutic antibodies through fruitful collaborations. Notably, the company has facilitated the development of Jemperli (dostarlimab-gxly), a PD-1 antagonist now partnered with GSK, and imsidolimab, an IL-36R antagonist, in collaboration with Vanda Pharmaceuticals.
Strategic Separation for Enhanced Focus
Recently, AnaptysBio has announced plans to separate its biopharmaceutical operations from its significant royalty assets by the end of 2026. This strategic move is designed to enable investors to better align their philosophies and portfolio management with the distinct opportunities and objectives that each new entity will present.
As AnaptysBio embarks on this pivotal phase, interested parties are encouraged to stay informed about their developing studies and corporate strategies. To keep up with their latest news and updates, follow their official website or social media channels.
Contact Information
For investor-related inquiries, please reach out to Nick Montemarano, Executive Director of Investor Relations, at:
Phone: 858.732.0178
Email: investors@anaptysbio.com
Frequently Asked Questions
What is AnaptysBio known for?
AnaptysBio is a biotechnology company focusing on the development of innovative therapeutics for autoimmune and inflammatory diseases.
When will the investor conferences take place?
The conferences are scheduled for December 2 and 3, 2025.
How can I access the live webcasts?
The webcasts will be available on the investor section of AnaptysBio's website, along with replay options for at least 30 days post-event.
What therapies are in AnaptysBio's pipeline?
Notable therapies include rosnilimab for rheumatoid arthritis and ANB033 for celiac disease, among others.
What are the company's future plans?
AnaptysBio plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing for a more focused investment strategy.
